Drug intelligence / Profile preview

Dermasectan (Novintethical Pharma)

Development stage
Unknown
Lead developer
Devintec
Modality
Device-based Delivery → Drug Delivery Systems
Administration
Topical
01

Overview

Dermasectan is a topical medical device developed by Novintethical Pharma for the management of atopic dermatitis, particularly in pediatric patients. It is formulated as a cream containing xyloglucan and pea protein, which act synergistically to form a protective, semi-permeable film on the skin surface. This "mucoprotective" barrier functions by physically preventing the penetration of allergens, irritants, and pathogens into the skin, which are common triggers for inflammatory flares in atopic dermatitis. By restoring the skin's barrier function and reducing transepidermal water loss, Dermasectan helps alleviate symptoms such as erythema, pruritus, and skin dryness. Clinical studies have evaluated its efficacy and safety as a non-pharmacological alternative or adjunct to standard-of-care topical corticosteroids like hydrocortisone.

Brand names
Dermasectan
Other names
Dermasectan cream

Beyond the preview

Go deeper on Dermasectan (Novintethical Pharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dermasectan (Novintethical Pharma).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call